
Legit.Health
Spain · HealthTech · Seed

Pleryon Therapeutics
China · Biotech & life sciences · Series A
Compatibility /100
52/100
High potentialWhy talk
- Complementary sectors: HealthTech × Biotech & life sciences — room for a joint offer or co-selling.
- Pleryon Therapeutics (Series A) is one step ahead of Legit.Health (Seed) — the freshest playbook for Legit.Health's next round.
- Legit.Health likely needs funding for the next round — Pleryon Therapeutics (China, Series A, $18.6M raised) can offer investor introductions (inferred from public profile).
Score anatomy
Each segment is what one dimension adds, out of 100.
Score by goal
Dimension by dimension
Needs ↔ offers
6.5 / 10 pts
Value flows both ways.
- Legit.Health likely needs funding for the next round — Pleryon Therapeutics (China, Series A, $18.6M raised) can offer investor introductions (inferred from public profile).
- Pleryon Therapeutics likely needs first paying customers — Legit.Health can offer access to its customer base (inferred from public profile).
Market bridge
2.5 / 10 pts
Distant markets.
- Pleryon Therapeutics is based in China (Asia): a landing pad on another continent, both ways.
Customer potential
2.5 / 5 pts
Some customer potential.
- Legit.Health has the customers Pleryon Therapeutics is still looking for — a channel Legit.Health can open.
Sector synergy
25.0 / 50 pts
Complementary sectors.
- Complementary sectors: HealthTech × Biotech & life sciences — room for a joint offer or co-selling.
Stage complementarity
15.0 / 25 pts
Useful peer or mentor link.
- Pleryon Therapeutics (Series A) is one step ahead of Legit.Health (Seed) — the freshest playbook for Legit.Health's next round.
How the score works
Each dimension gives a value between 0 and 1, multiplied by its weight; the compatibility is the sum (0–100). Weights for “Peers”: Needs ↔ offers 10, Market bridge 10, Customer potential 5, Sector synergy 50, Stage complementarity 25. Declared needs and offers count fully; when a startup has declared nothing, a few needs/offers are inferred from its public profile (for example, no known traction ⇒ needs customers) and count at half value.
Potential blends compatibility (65%) with the mean global score of both startups (35%): 54/100 — high from 50, medium from 36.